Parogrelil
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2003 (NCT00102050)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 3AINHIBITOR
PDE3A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2h)-pyridazinone hydrochloride
- nm-702
- nm-702
- nm-702
- nm-702
- nt 702
- nt-702
- nt702 cpd
- parogrelil hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00102050 | Phase 2 | Apr 1, 2003 | Nissan Chemical Industries |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nissan Chemical Industries | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1